Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? (2016)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.atherosclerosis.2016.02.018
- Subjects: MUTAÇÃO GENÉTICA; LIPÍDEOS; ANTICORPOS MONOCLONAIS; HIPERCOLESTEROLEMIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Atherosclerosis
- ISSN: 0021-9150
- Volume/Número/Paginação/Ano: v. 248, n. 1, p. 62-75, 2016
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BANERJEE, Yajnavalka et al. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. Atherosclerosis, v. 248, n. 1, p. 62-75, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.atherosclerosis.2016.02.018. Acesso em: 27 jan. 2026. -
APA
Banerjee, Y., Santos, R. D., Al-Rasadi, K., & Rizzo, M. (2016). Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Atherosclerosis, 248( 1), 62-75. doi:10.1016/j.atherosclerosis.2016.02.018 -
NLM
Banerjee Y, Santos RD, Al-Rasadi K, Rizzo M. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? [Internet]. Atherosclerosis. 2016 ; 248( 1): 62-75.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2016.02.018 -
Vancouver
Banerjee Y, Santos RD, Al-Rasadi K, Rizzo M. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? [Internet]. Atherosclerosis. 2016 ; 248( 1): 62-75.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2016.02.018 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
- Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia
- Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
- Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients
- Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
- Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications?
- Sodium intake and prevalence of hypertension in elementary school students
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab
Informações sobre o DOI: 10.1016/j.atherosclerosis.2016.02.018 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
